Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pedro Cox-Alomar

Cardiovascular Disease Miami, FL Medical Doctor

NPI 1467643213 CMS profile 718465

1321 Nw 14Th St Ste 510, Miami, FL 33125

Open in the dashboard

General payments

$89,334

436 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,614 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Pedro Cox-Alomar of Miami, FL is reported in the CMS Open Payments database as having received $89,334 across 436 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,614 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,871 44
2024 General $6,737 81
2023 General $16,795 69
2022 General $30,513 92
2021 General $20,412 76
2020 General $3,123 32
2019 General $7,883 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pedro Cox-Alomar
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Pedro Cox-Alomar were reported at $3,871. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Pedro Cox-Alomar Cardiovascular Disease median Middle half National median
2019 $7,883 $450 $127–$1,392 $163
2020 $3,123 $242 $77–$751 $114
2021 $20,412 $335 $101–$1,037 $132
2022 $30,513 $395 $121–$1,211 $149
2023 $16,795 $443 $136–$1,283 $160
2024 $6,737 $450 $136–$1,323 $164
2025 $3,871 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $66,419 186 payments
  2. Medtronic, Inc. $11,382 76 payments
  3. Boston Scientific Corporation $5,133 75 payments
  4. W. L. Gore & Associates, Inc. $1,450 21 payments
  5. Medtronic Vascular, Inc. $987 12 payments
  6. Shockwave Medical, Inc $788 12 payments
  7. Abbott Laboratories $717 8 payments
  8. Abiomed $519 9 payments
  9. Penumbra, Inc. $407 3 payments
  10. AngioDynamics, Inc. $251 3 payments
  11. Other $1,281 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $40,538 13 payments
  2. Food and Beverage $24,003 368 payments
  3. Travel and Lodging $18,481 52 payments
  4. Honoraria $4,750 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,563 1 payment
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $47,309 72 payments
  2. COREVALVE EVOLUT R $8,681 37 payments
  3. Edwards SAPIEN 3 Transcatheter Heart Valve $7,253 19 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $5,363 28 payments
  5. CoreValve Evolut Transcatheter Valve Systems $1,382 13 payments
  6. GORE CARDIOFORM Septal Occluder $1,305 20 payments
  7. WATCHMAN FLX $1,020 10 payments
  8. CoreValve Evolut Transcatheter Valve Systems $842 11 payments
  9. SAPIEN 3 Ultra RESILIA $730 15 payments
  10. Sentinel $719 8 payments
  11. Other $9,417 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

109

Median for Interventional Cardiology: 2,236

Drug cost

$21,010

Median for Interventional Cardiology: $380,412

Branded share of claims

62.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $13,242
Brilinta Ticagrelor Brand 12 $7,400
Atorvastatin Calcium Generic 27 $161
Clopidogrel Clopidogrel Bisulfate Brand 33 $158
Amlodipine Besylate Generic 14 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$56,075

Medicare's payments for the services billed

Medicare patients

208

Average age 74

Services billed

414

79 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 50%
Diabetes 47%
Chronic kidney disease 47%
Heart failure 45%
Atrial fibrillation 37%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record